Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Prolexys Pharmaceuticals has started a Phase I study of its investigational cancer candidate designed to evaluate the safety, pharmacokinetic and pharmacodynamic properties of the drug in patients with advanced solid tumors.
Subscribe to our email newsletter
The first Phase I study of the compound, PRLX 93936, will be a dose-escalating trial involving up to 36 patients. PRLX 93936 is a structural analog of a compound called erastin, in-licensed by Prolexys from the MIT/Whitehead Institute in January 2005.
PRLX 93936 was tested against a series of normal and tumor cell lines derived from tumors with dissimilar causative mutations, indicating potent and selective activity against a wide variety of tumors, many with activated Ras pathway.
The compound showed robust tumor regression in a range of human tumor xenografts grown in immuno-compromised mice, including models of pancreatic, colon, and ovarian cancers, and melanoma, fibrosarcoma and other solid tumors.